Literature DB >> 12201791

Prospective study designs in outcomes research: the case of migraine.

Elizabeth A Rothermich1, Meryl I Brod, Warren H Schonfeld, Clayton R Rowland, Baltazar Gomez-Mancilla.   

Abstract

Patient-reported outcomes (PROs), including resource utilisation, productivity and quality of life, are important outcomes in the field of migraine. Clinical trials have begun to incorporate PROs; however, not all research questions can be answered fully within the framework of a clinical trial design. Other prospective designs, including effectiveness trials, observational studies, and study hybrids may be used to answer many of the different research questions related to PROs. This paper reviews prospective study designs, their strengths and weaknesses, and examples of their application in migraine health-outcomes research. Guidance is provided for researchers in the selection of prospective research designs and the incorporation of PROs-research objectives.

Entities:  

Mesh:

Year:  2002        PMID: 12201791     DOI: 10.2165/00019053-200220110-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

2.  Randomized trials or observational tribulations?

Authors:  S J Pocock; D R Elbourne
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 3.  Common errors and controversies in pharmacoeconomic analyses.

Authors:  S Byford; S Palmer
Journal:  Pharmacoeconomics       Date:  1998-06       Impact factor: 4.981

4.  Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial.

Authors:  R C Cady; R Ryan; P Jhingran; S O'Quinn; D G Pait
Journal:  Arch Intern Med       Date:  1998-05-11

5.  A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity.

Authors:  P Cortelli; C Dahlöf; J Bouchard; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

6.  A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life.

Authors:  C Dahlöf; J Bouchard; P Cortelli; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

7.  Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.

Authors:  J H Lofland; N E Johnson; A S Batenhorst; D B Nash
Journal:  Arch Intern Med       Date:  1999-04-26

8.  Quality of life assessment among migraine patients treated with sumatriptan.

Authors:  G D Solomon; F G Skobieranda; J R Genzen
Journal:  Headache       Date:  1995-09       Impact factor: 5.887

9.  Improvements in health-related quality of life with sumatriptan treatment for migraine.

Authors:  P Jhingran; R K Cady; J Rubino; D Miller; R B Grice; D L Gutterman
Journal:  J Fam Pract       Date:  1996-01       Impact factor: 0.493

10.  Health-related quality of life under six months' treatment of migraine--an open clinic-based longitudinal study.

Authors:  C G Dahlöf
Journal:  Cephalalgia       Date:  1995-10       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.